Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Shares Outstanding: 2014-2025

Historic Shares Outstanding for Viking Therapeutics (VKTX) over the last 9 years, with Sep 2025 value amounting to $112.4 million.

  • Viking Therapeutics' Shares Outstanding rose 0.91% to $112.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.4 million, marking a year-over-year increase of 0.91%. This contributed to the annual value of $111.6 million for FY2024, which is 11.45% up from last year.
  • Viking Therapeutics' Shares Outstanding amounted to $112.4 million in Q3 2025, which was up 0.10% from $112.3 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Shares Outstanding ranged from a high of $112.4 million in Q3 2025 and a low of $76.7 million during Q2 2022.
  • Over the past 3 years, Viking Therapeutics' median Shares Outstanding value was $110.8 million (recorded in 2024), while the average stood at $105.5 million.
  • In the last 5 years, Viking Therapeutics' Shares Outstanding decreased by 1.98% in 2022 and then soared by 38.97% in 2024.
  • Quarterly analysis of 5 years shows Viking Therapeutics' Shares Outstanding stood at $78.2 million in 2021, then climbed by 0.01% to $78.3 million in 2022, then rose by 27.93% to $100.1 million in 2023, then grew by 11.45% to $111.6 million in 2024, then increased by 0.91% to $112.4 million in 2025.
  • Its Shares Outstanding stands at $112.4 million for Q3 2025, versus $112.3 million for Q2 2025 and $112.3 million for Q1 2025.